The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

The latest trading session saw Amgen (AMGN) ending at $310.09, denoting a +1.44% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 4.84%. On the ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...

The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

In a report released today, DBS also maintained a Buy rating on the stock with a $365.00 price target. The company has a one-year high of $346.85 and a one-year low of $253.30. Currently ...